Objectives: To assess the impact of all-oral direct-acting antiviral agent (DAA) regimens on the risk of hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients with cirrhosis.
Introduction
Liver cancer is the sixth most common cancer worldwide and the fourth most common cause of cancer death according to the Global Burden of Disease Liver Cancer Collaboration's last report. 1 In addition, hepatocellular carcinoma (HCC) is the leading cause of death among patients with cirrhosis. 2 Notably, liver cancer incident cases increased by 75% between 1990 and 2015, mainly driven by cases due to chronic HCV infection. In developed countries, cirrhosis due to HCV infection is the main risk factor for HCC. 1, 2 Previous reports have estimated that the cumulative incidence of HCC in untreated patients with HCV-related cirrhosis is 3%-5% per year. [3] [4] [5] As HCV coinfection is frequent in HIVinfected individuals owing to shared risk factors for the acquisition of both viruses, HIV/HCV-coinfected patients are a high-risk population for the emergence of HCC. Indeed, worldwide data indicate that the incidence and mortality of HCC have increased in HIV-infected patients. [6] [7] [8] The best preventive intervention against HCC in HCVinfected patients with or without HIV infection so far has been viral eradication, as the achievement of sustained virological response (SVR) with IFN-based regimens has been associated with a reduction in the risk of developing HCC. [9] [10] [11] [12] [13] [14] [15] [16] [17] Direct-acting antiviral agents (DAAs) have become the standard for HCV treatment, with high cure rates, including for patients with cirrhosis. 18 Although it has been assumed that the consecution of SVR with the use of IFN-free DAA regimens will provide a similar protective effect with regard to the risk of HCC, this effect has to be proven. Previous reports on this issue have initially yielded conflicting data, as some studies have suggested that DAA use could be associated with a higher risk of HCC development or recurrence, [19] [20] [21] [22] whereas other studies have not found evidence of an increased risk after DAA use. [23] [24] [25] [26] [27] Recent analyses of three large retrospective cohorts of HCV-mono-infected patients have suggested that DAA use is not only harmless, but also reduces the risk of HCC when SVR is achieved. [28] [29] [30] It is not known whether SVR to all-oral DAA impacts the risk of HCC in HIV-coinfected patients. HCV-related cirrhosis follows an accelerated course in those also infected by HIV. 31, 32 Besides, it has been suggested that the time from HCV infection to the development of HCC is shorter in the setting of HIV infection. [33] [34] [35] Moreover, HIV-coinfected patients responded worse to DAA than HCV-mono-infected individuals in a recent real-life study. 36 Consequently, the benefit of SVR to DAA with regard to the risk of HCC could theoretically be less marked and, thus, needs to be specifically proven in this scenario.
For these reasons, the objective of this study was to assess the impact of treatment with all-oral DAA regimens on the risk of HCC in HIV/HCV-coinfected patients with cirrhosis.
Patients and methods

Study design and patients
The HEPAVIR cirrhosis cohort (ClinicalTrials.gov ID: NCT02693847) is a prospective cohort study recruiting HIV/HCV-coinfected patients with a new diagnosis of cirrhosis from seven hospitals in Andalusia in Southern Spain. Since February 2006, all consecutive patients with a new diagnosis of cirrhosis, as indicated by a first determination of liver stiffness (LS) 14 kPa, have been included in the cohort, provided that they show detectable HCV RNA at inclusion and no evidence of autoimmune or metabolic liver disease. Patients with a previous or concomitant liver decompensation at diagnosis of cirrhosis were not included. For the present analysis, patients with hepatitis B virus coinfection were excluded.
Follow-up
The management of cirrhosis in the cohort was done according to a specific protocol of care created by the investigating team at the conception of the cohort and modified throughout study period according to new evidence and the updates of clinical guidelines. 37 Patients were evaluated at least every 6 months, including clinical visits focusing on the early detection of liver decompensations and the performance of routine laboratory examinations. The prevention, diagnosis and management of liver decompensations other than HCC were performed as previously described.
37
HCC surveillance and diagnosis HCC surveillance was performed in the cohort according to the recommendations of Spanish and international guidelines in force during the study period. [38] [39] [40] [41] [42] Thus, surveillance of HCC was done by the performance of an abdominal ultrasound examination at diagnosis of cirrhosis and thereafter every 6 months. In patients who achieved SVR, ultrasound HCC surveillance was maintained during the entire follow-up. HCC diagnosis was done according to the American Association for the Study of Liver Diseases criteria. 40, 41 Treatment of hepatitis C During the study period, hepatitis C was treated according to the availability of drugs and the recommendations of international and national guidelines in force. The final decision on the combination to use was made by the caring physician. All-oral DAA regimens included the combinations of sofosbuvir plus ribavirin, sofosbuvir plus daclatasvir with or without ribavirin, sofosbuvir plus simeprevir with or without ribavirin, sofosbuvir/ledipasvir with or without ribavirin, sofosbuvir/velpatasvir with or without ribavirin, ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin, and ombitasvir/paritaprevir/ritonavir with ribavirin. SVR was defined as undetectable plasma HCV RNA 12 or 24 weeks after the scheduled end of therapy.
Data analysis
Patients were prospectively seen until HCC, death or the censoring date (31 March 2017). HCC diagnoses, vital status and causes of death were obtained from clinical records. Patients lost to follow-up or their next of kin were contacted via telephone whenever possible. In patients lost to followup, the electronic clinical record of each patient, which all public health institutions in Andalusia share, was also accessed.
Continuous variables are expressed as median (IQR) whereas categorical variables are presented as number (%). Continuous variables were compared by means of the Mann-Whitney U-test.
The primary endpoint of the study was the emergence of HCC. The overall incidence rate (IR) (95% CI) of HCC and the IR of HCC in different groups according to treatment strategies against HCV during follow-up were computed. The IR of HCC was calculated as the number of new cases of HCC in each group per 100 person-years (PY). For these analyses, patients were divided into five groups: (i) no therapy during follow-up; (ii) only IFN-based regimens without achieving SVR; (iii) only IFN-based regimens with SVR; (iv) all-oral DAA regimens without achieving SVR; and (v) all-oral DAA regimens with SVR. Patients receiving all-oral DAA regimens during follow-up who were previously treated with IFN-based regimens were classified as group (iv) or (v), depending on the response. For patients who received multiple courses of therapy, the most recent course of therapy was considered for classification purposes. Patients who started an all-oral DAA who were still on treatment or had not reached the 12 week post-therapy evaluation timepoint by the censoring date were considered to not have SVR. Additionally, patients were also classified as ever exposed to an all-oral DAA regimen or not. In those patients developing an HCC during follow-up, only HCV treatment before HCC emergence was considered. Comparisons of the IR of HCC were performed by the exact Poisson test. Time-to-event analyses were performed to identify predictors of HCC emergence during follow-up. For these analyses, the date of the first transient elastography (TE) examination that established the diagnosis of cirrhosis was considered the baseline timepoint. The time to event was computed as the time elapsed from baseline to the emergence of HCC. Kaplan-Meier estimates of Merchante et al.
the cumulative probability of survival were compared using the log-rank test. Those variables with a P value 0.1 on univariate analyses were entered in multivariate competing-risk models, which also included age and sex. For these analyses, death from any cause during follow-up was considered a competing event for HCC. Associations with P , 0.05 were considered significant. The subhazard ratio and the corresponding 95% CI were calculated. The statistical analysis was carried out with the SPSS statistical software package release 24.0 (IBM Corporation, Somers, NY, USA) and Stata SE 9.0 (Statacorp, College Station, TX, USA).
Ethics
The study was designed and conducted following the Helsinki declaration. The ethics committee of the Hospitales Universitarios Virgen Macarena and Virgen del Rocío approved the study (promoter code PI-0014-2014; internal code 0729-N-15) on 17 November 2015.
Results
Features of the study population
Four hundred and ninety-five patients were included in the study. The main characteristics of the study population are summarized in Table 1 .
One hundred and thirty-three (27%) patients had undergone a previous TE examination that showed an LS ,14 kPa. The median (IQR) elapsed time from that examination was 14 (10-23) months and the median (IQR) LS was 10 (8-12) kPa. In the remaining 362 (73%) patients, the TE that led to the diagnosis of cirrhosis was the first TE examination.
The median (IQR) follow-up was 59 (27-84) months. During the follow-up, 87 (17.6%) patients died, 3 (0.6%) underwent a liver transplant and 57 (11.5%) were lost to follow-up. Table S1 (available as Supplementary data at JAC Online) summarizes the characteristics of patients lost to follow-up, who were comparable with the remaining patients. Death was liver related in 48 (55%) patients, whereas 2 deaths were attributable to AIDS, 10 were due to neoplasm other than HCC and 27 were due to other non-liver-related causes. Although classified as non-liver related, some episodes of death caused by infection events or non-Hodgkin lymphoma also had a potential link to cirrhosis or chronic HCV infection. HCC accounted for 11 (23%) of 48 liver-related deaths. Table 2 summarizes the episodes of first liver decompensation and the causes of death during follow-up. 
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Treatment of hepatitis C during the follow-up
Three hundred and sixty-six (74%) patients received therapy during follow-up: 106 patients received only IFN-based regimens and 260 received all-oral DAA regimens. Among those treated with an all-oral DAA regimen, 87 had been previously treated during follow-up with an IFN-based regimen without achieving SVR. Overall, 303 (61%) of the 495 patients achieved SVR during follow-up, 79 after IFN-based regimens and 224 after an all-oral DAA regimen. Fifteen patients of those who started an all-oral DAA were still on treatment or had not reached 12 weeks after the end of therapy at the censoring date. The median (IQR) follow-up after SVR was 34 (19-64) months for those who achieved SVR after IFN-based regimens and 10 (5-15) months for those who achieved SVR with all-oral DAA regimens (P , 0.0001). The median elapsed time from the diagnosis of cirrhosis to the achievement of SVR was 21 (14-40) months for those cured with IFN-based regimens and 60 (34-75) months for those who achieved SVR with an all-oral DAA regimen (P , 0.0001).
Overall incidence of HCC during the follow-up
Twenty-two (4.4%; 95% CI 2.6-6.3) patients developed an HCC during follow-up. The overall IR of HCC was 0.93 (95% CI 0.06-1.42) per 100 PY after 2351.91 PY of follow-up (Table 3 ). The cumulative probability of HCC at 1, 3 and 5 years was 1%, 3% and 5%, respectively.
Probability of HCC emergence during the follow-up according to HCV therapy
The occurrence of SVR during the follow-up was associated with a lower probability of developing HCC (Figure 1a) . Figure 1(b) shows the probability of remaining free of HCC emergence during followup according to HCV therapy strategy and response. SVR after an all-oral DAA regimen was associated with a lower probability of HCC emergence when compared with not receiving therapy or receiving HCV therapy without achieving SVR (Figure 1b) . In an analysis restricted to patients achieving SVR during the follow-up, there were no differences in the probability of HCC emergence In those patients with more than one liver decompensation during follow-up, the first liver decompensation is indicated. Specific causes of death are listed in the footnotes below. Pneumocystis jirovecii pneumonia (n " 2). c Oral cavity cancer (n " 2), pancreatic cancer (n " 2), laryngeal cancer (n " 2), breast cancer (n " 1), non-Hodgkin lymphoma (n " 1), lung cancer (n " 1), renal cancer (n " 1). d Community-acquired pneumonia (n " 7), aspiration pneumonia secondary to neurogenic dysphagia (n " 1), acute cholangitis (n " 1).
e Spontaneous cerebrovascular bleeding (n " 4), drug overdose (n " 3), traumatic cerebrovascular bleeding (n " 2), sudden death (n " 2), intra-abdominal bleeding (n " 1), traffic accident (n " 1), suicide (n " 1), pulmonary hypertension (n " 1), dementia (n " 1), acute renal failure other than hepatorenal syndrome (n " 1), acute myocardial infarction (n " 1).
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among patients achieving SVR after an all-oral DAA regimen when compared with those achieving SVR with IFN-based regimens (P " 0.2). Table 3 shows the IR of HCC according to HCV therapy and response. IR (95% CI) of HCC among those who achieved SVR during follow-up was 0.23 (0.08-0.62) per 100 PY, which was significantly lower than that observed among those who did not clear the virus during follow-up (Table 3 ). The treatment strategy that led to SVR did not influence HCC outcomes. Thus, the IR of HCC was not statistically different between patients who cleared HCV after an IFNbased regimen and those who achieved SVR after an all-oral DAA combination (P " 0.27) ( Table 3 ). The IR (95% CI) of HCC after SVR to an all-oral DAA treatment was 0.32 (0.12-0.86) per 100 PY (Table 3) . In order to exclude the possibility that DAA exposure was associated with a higher risk of HCC, we assessed the IR of HCC among those who ever received an all-oral DAA regimen during follow-up, either with or without the occurrence of SVR. Patients who were still receiving treatment or who had not reached the SVR evaluation timepoint yet were also included in such analysis. The IR of HCC in this group was significantly lower than that observed in the remaining cohort (Table 3) .
IR of HCC during the follow-up according to HCV therapy
Independent predictors of HCC emergence during follow-up
After multivariate competing-risk analyses adjusted by sex and Child-Pugh stage, age, baseline a-fetoprotein and, as a protective factor, achieving SVR (either with IFN-based or with an all-oral DAA treatment) were independent predictors of HCC (Table 4) .
Discussion
This study demonstrated that achieving SVR with all-oral DAA regimens reduces the risk of HCC in HIV/HCV-coinfected patients with cirrhosis. According to our results, a 74% reduction in HCC risk is expected when compared with no therapy in these patients. HCC risk reduction with DAA seems to be similar to that provided by the occurrence of SVR with IFN-based regimens. Finally, exposure to DAA was associated with significantly lower IRs of HCC. Consequently, we found no evidence for an increased risk of HCC with the use of these agents.
Although it has been assumed that the benefit of SVR after the use of all-oral DAA regimens with regard to the risk of HCC would be comparable to what has been observed with IFN-based therapies, many experts have claimed that this effect needs to be proven. 43, 44 A risk reduction of HCC after the achievement of SVR with DAA has been previously suggested by three large retrospective studies conducted in HCV-mono-infected patients. [28] [29] [30] Backus et al. 28 found an 84% HCC risk reduction after SVR to DAA compared with treated patients without SVR in a retrospective analysis of a cohort of patients with advanced liver disease, which they defined by an FIB-4 score .3.25. In that study, the IR of HCC after SVR was 1.9 per 100 PY. 28 In another retrospective analysis of patients treated with DAA, 36% of them with cirrhosis, Kanwal et al. 29 also found a reduced risk of HCC in patients with SVR. The IR of HCC in the subgroup of cirrhotics who achieved SVR was 1.82 per 100 PY. 29 Finally, Ioannou et al. 30 have retrospectively assessed the impact of SVR to different treatment strategies in patients who started antiviral treatment in the US Veterans Affairs national healthcare system and reported a 71% reduction in risk after SVR to DAA compared with non-responder patients. Of note, SVR was associated with a similar decreased risk of HCC irrespective of whether the antiviral treatment was IFN based or not, 30 which is in line with our results. In this study, the IR of HCC was 1.97 per 100 PY among those with cirrhosis and SVR, irrespective of the regimen used. 30 The IR of HCC after SVR to an all-oral DAA treatment in our study was 0.32 per 100 PY, a lower figure than those observed in the above-mentioned studies [28] [29] [30] and lower than what has been reported after SVR to IFN-based therapies. 15, 45, 46 In a large retrospective study of HCV-mono-infected US veterans treated with IFN-based regimens, the annual incidence of HCC after SVR was 1.39% among those with a cirrhosis diagnostic code. 45 In another retrospective study of patients previously cured with IFN therapies, IR of HCC after SVR was 0.95 among those with previous cirrhosis, which was mainly diagnosed by liver biopsy. 46 Differences between the IRs of HCC after SVR in our study and those found in previous IFN-free or IFN-based studies probably reflect differences in the severity of underlying cirrhosis across studies. As an example, in the study by Backus et al., 28 26% of patients had a previous history of decompensated cirrhosis. Presumably an earlier diagnosis of cirrhosis in our study has contributed to the lower rates of HCC. Thus, patients with a previous decompensation of cirrhosis are not included. Besides, diagnosis of cirrhosis was made by a first LS measurement indicative of cirrhosis in a population who, in a substantial proportion of cases, underwent routine sequential measurements of LS. Our findings also suggest that the sooner SVR occurs in the course of cirrhosis, the better it is in terms of HCC prevention. IFN-based refers to patients who received only IFN-based regimens. Alloral DAA refers to patients receiving all-oral DAA regimens, whether or not they were previously treated with an IFN-based regimen. For these analyses, the date of the first TE examination that established the diagnosis of cirrhosis was considered the baseline timepoint to compute PY of follow-up.
SVR with DAA reduces HCC risk in HIV
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There was a lack of prospective data assessing the impact of DAA/IFN-free regimens on the risk of HCC in the specific setting of HIV coinfection. In a recent retrospective analysis of the multicentre GEHEP-002 cohort in Spain, 47 the frequency of de novo HCC after SVR with DAA/IFN-free regimens in 911 HIV/HCV-coinfected patients with cirrhosis was 0.88%, lower than the 15% rate that was observed after SVR with pegylated-IFN plus ribavirin in the same centres. Although these data suggested a risk reduction of No therapy Figure 1 . Probability of remaining free of HCC (a) in relation to achievement of sustained virological response and (b) in relation to treatment strategy and type of response. IFN-based refers to patients who received only IFN-based regimens. DAA refers to patients receiving all-oral DAA regimens, whether or not they were previously treated with an IFN-based regimen. For these analyses, the date of the first TE examination that established the diagnosis of cirrhosis was considered the baseline timepoint.
HCC with DAA use, the IR of HCC could not be assessed in that study owing to incomplete information on follow-up owing to the retrospective design. Hasson et al. 48 reported the occurrence of three cases of HCC during or after all-oral DAA therapy in 118 HIV/HCVcoinfected patients with advanced fibrosis. Those authors concluded that the 2.5% frequency of HCC was not higher than expected, but there was no comparator group from which any definitive conclusions could be drawn. Finally, Kanwal et al. 29 estimated that the IR of HCC after SVR to DAA was 0.60 per 100 PY in a subgroup of HIV-coinfected patients included in their large retrospective cohort. Unfortunately, information on the proportion of patients with cirrhosis was not provided. Of note, HIV coinfection was not an independent risk factor for HCC development in that study, 29 which is consistent with the relatively low rates of HCC found in our study after the use of DAA.
This study has some limitations. First, all-oral DAAs have been widely used only in the last few years of the follow-up. Thus, a potential limitation is the shorter duration of observation after the use of all-oral DAA regimens, compared with patients receiving IFN-based treatment. This may underestimate the incidence of HCC after the use of DAAs. However, the median follow-up after DAA use in our study was comparable with that of previous studies in HCV-mono-infected patients. [28] [29] [30] Besides, the elapsed time from the diagnosis of cirrhosis to the start of therapy was significantly longer in DAA patients than in the IFN-based group in our cohort. This is a relevant factor that has not been controlled in other studies, [28] [29] [30] and may, at least partially, counterbalance the former limitation. Second, our cohort was composed exclusively of HIV-coinfected patients without decompensated cirrhosis at the diagnosis of cirrhosis. Consequently, extrapolation of our observations to those with more advanced liver disease should be made cautiously. Third, the analysis of predictors of HCC emergence was somewhat limited in its ability to evaluate the potential impact of other comorbidities, such as the metabolic syndrome, which has been associated with the development of HCC after SVR in a previous study. 49 On the other hand our study has several strengths.
First, this was a prospective, well-defined cohort of patients with a known date of diagnosis of cirrhosis, which was made by a reliable and uniform procedure, TE. This makes it possible to control for the duration of cirrhosis prior to therapy and avoids the limitations of previous retrospective studies. Second, HCC surveillance was performed in all patients according to current recommendations, making it very unlikely that HCC diagnosis or bias due to inconsistent HCC surveillance was underreported, a main limitation of retrospective studies. [28] [29] [30] Third, our analysis includes an untreated control group, which was lacking in other studies, 29 and a control group of IFN-based treated patients, all within the same prospective cohort, allowing comparisons to be made.
Conclusions
Eradication of HCV with all-oral DAA regimens notably reduces the risk of HCC in HIV/HCV-coinfected patients with cirrhosis. As it is recommended after SVR to IFN-based therapies, surveillance for HCC after SVR to DAA should be maintained in cirrhotics, as residual risk of liver cancer still persists. Future studies should clarify whether there is a definite point beyond which HCC risk after SVR is low enough to discontinue surveillance. Identification and elimination of risk factors for HCC are key elements in achieving a sustained reduction in liver cancer burden. From this perspective, improving the accessibility and affordability of all-oral DAA regimens is a critical step in reducing the incidence of HCC in the coming years in the HCV-infected population with or without HIV coinfection.
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